H. Zarour

发表

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

J. Badger, D. Davar, A. Dzutsev, 2021, Science.

Emerging Opportunities and Challenges in Cancer Immunotherapy

H. Zarour, S. Demaria, I. Melero, 2016, Clinical Cancer Research.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

J. Lunceford, J. Wolchok, H. Zarour, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2014, The Lancet.

Immunotherapy of cancer in 2012

J. Kirkwood, H. Zarour, L. Butterfield, 2012, CA: a cancer journal for clinicians.

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

J. Wolchok, H. Zarour, A. Ribas, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T Cells Induced by Melanoma Vaccines + CD 8 Specific − PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2014 .

Microenvironment and Immunology PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen – Speci fi c CD 8 þ T Cells Induced by Melanoma Vaccines

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2014 .

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Hong Wang, Joe-Marc Chauvin, Ornella Pagliano, 2013, Cancer research.

Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins

H. Zarour, A. Ménez, B. Maillère, 2007, European journal of immunology.

Study of sunbathing habits in children and adolescents: application to the prevention of melanoma.

H. Zarour, J. Grob, J. Bonerandi, 1993, Dermatology.

Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling.

H. Zarour, M. Mandić, A. Lokshin, 2007, Cancer research.

Immunomodulatory effects of high‐dose and low‐dose interferon α2b in patients with high‐risk resected melanoma

J. Sosman, J. Kirkwood, H. Zarour, 2002 .

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

J. Sosman, J. Kirkwood, H. Zarour, 2002, Cancer.

Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.

J. Lunceford, J. Wolchok, H. Zarour, 2014 .

Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome

J. Lunceford, J. Wolchok, H. Zarour, 2014 .

Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.

J. Fay, J. Wolchok, M. Atkins, 2014 .

NY-ESO-1 Encodes DRB 1 * 0401-restricted Epitopes Recognized by Melanoma-reactive CD 4 1 T Cells 1

V. Brusic, J. Kirkwood, H. Zarour, 2000 .

Breast Cancers TRAG-3 in Patients with Melanoma and T Cell Responses against + Spontaneous CD 4 Maillere and

J. Kirkwood, H. Zarour, A. Brufsky, 2006 .

IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell

Joe-Marc Chauvin, H. Zarour, V. Hornung, 2019, Cancer Immunology Research.

Cancer immunotherapy: Progress and challenges in the clinical setting

H. Zarour, S. Ferrone, 2011, European journal of immunology.

Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.

J. Lunceford, T. Mcclanahan, M. Ayers, 2015 .

Melanoma vaccines: early progress and future promises.

J. Kirkwood, H. Zarour, 2003, Seminars in cutaneous medicine and surgery.

scMAPA: Identification of cell-type–specific alternative polyadenylation in complex tissues

Robert M. Morrison, H. Zarour, Yidi Qin, 2022, GigaScience.

Role of sun exposure on nevus. First study in age-sex phenotype-controlled populations.

H. Zarour, J. Grob, M. Richard, 1993, Archives of dermatology.

Genes coding for melanoma antigens recognised by cytolytic T lymphocytes

H. Zarour, P. Coulie, F. Brasseur, 1997, Eye.

The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100.

H. Zarour, J. Renauld, P. Romero, 1996, The Journal of investigative dermatology.

Tim-3 mediates T cell trogocytosis to limit antitumor immunity

Simon C Watkins, D. Davar, Joe-Marc Chauvin, 2022, The Journal of clinical investigation.

Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi

Amy Rose, J. Kirkwood, H. Zarour, 2018, Cancer Prevention Research.

Human Tumor Antigen-Specific Helper and Regulatory T Cells Share Common Epitope Specificity but Exhibit Distinct T Cell Repertoire

J. Kirkwood, H. Zarour, P. Kúdela, 2010, The Journal of Immunology.

RepertoireSpecificity but Exhibit Distinct T Cell Regulatory T Cells Share Common Epitope Human Tumor Antigen-Specific Helper and

J. Kirkwood, H. Zarour, P. Kúdela, 2010 .

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

J. Wolchok, H. Zarour, N. Ibrahim, 2019 .

Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients

J. Kirkwood, H. Zarour, A. Donnenberg, 2008, Journal of immunotherapy.

Peptide-Binding Specificity Molecule , Defines a New Supertype of HLA-DP 4 , the Most Frequent HLA II

H. Zarour, A. Ménez, B. Maillère, 2002 .

Predicting cancer immunotherapy response from gut microbiomes using machine learning models

H. Kong, D. Davar, A. Dzutsev, 2022, Oncotarget.

PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients1

J. Kirkwood, H. Zarour, S. Ferrone, 2009, The Journal of Immunology.

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

J. Wolchok, J. Kirkwood, H. Zarour, 2021, Oncoimmunology.

One NY-ESO-1-Derived Epitope That Promiscuously Binds to Multiple HLA-DR and HLA-DP4 Molecules and Stimulates Autologous CD4+ T Cells from Patients with NY-ESO-1-Expressing Melanoma1

V. Brusic, J. Kirkwood, H. Zarour, 2005, The Journal of Immunology.

NY-ESO-1-Expressing Melanoma T Cells from Patients with + Autologous CD 4 and HLA-DP 4 Molecules and Stimulates Promiscuously Binds to Multiple HLA-DR One NY-ESO-1-Derived Epitope That

V. Brusic, J. Kirkwood, H. Zarour, 2005 .

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

J. Wolchok, H. Zarour, N. Ibrahim, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers1

J. Kirkwood, H. Zarour, A. Brufsky, 2006, The Journal of Immunology.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

James R. Anderson, J. Wolchok, H. Zarour, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Strategies to reverse melanoma-induced T-cell dysfunction.

H. Zarour, J. Fourcade, 2013, Clinics in dermatology.

Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.

J. Wolchok, H. Zarour, A. Ribas, 2015 .

The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019

P. Ascierto, H. Zarour, A. Testori, 2020, Journal of Translational Medicine.

Epitope Hierarchy of Spontaneous CD4+ T Cell Responses to LAGE-1

J. Kirkwood, H. Zarour, B. Maillère, 2011, The Journal of Immunology.

Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading

J. Kirkwood, H. Zarour, M. Lotze, 2000, Immunological investigations.

Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.

J. Wolchok, H. Zarour, A. Ribas, 2015 .

721 Pixatimod (P) in combination with nivolumab (N) +/- low-dose cyclophosphamide (Cy) in advanced cancers: a phase IIA basket trial

Hong Wang, D. Davar, Amy Rose, 2022, Regular and Young Investigator Award Abstracts.

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

D. Davar, Joe-Marc Chauvin, Carmine Menna, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

J. Wolchok, H. Zarour, A. Ribas, 2015 .

LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES

J. Wolchok, H. Zarour, A. Ribas, 2014 .

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma

Hong Wang, D. Davar, Y. Najjar, 2022, Frontiers in Oncology.

Extra-anogenital HPV16-related bowenoid papulosis.

H. Zarour, J. Grob, J. Bonerandi, 1991, Genitourinary medicine.

Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy

D. Davar, H. Zarour, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2013, The New England journal of medicine.

Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France.

H. Zarour, J. Grob, M. Richard, 1995, Dermatology.

Palmoplantar orthokeratotic filiform hyperkeratosis in a patient with associated Darier's disease. Classification of filiform hyperkeratosis.

H. Zarour, J. Grob, J. Bonerandi, 1992, Dermatology.

Large keratoacanthomas treated with intralesional interferon alfa-2a.

H. Zarour, J. Grob, M. Richard, 1993, Journal of the American Academy of Dermatology.

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

J. Kirkwood, H. Zarour, V. Kuchroo, 2010, The Journal of experimental medicine.

Next generation of immunotherapy for melanoma.

J. Kirkwood, H. Zarour, L. Butterfield, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma.

L. Xerri, H. Zarour, J. Grob, 1995, Archives of dermatology.

TIGIT in cancer immunotherapy

Joe-Marc Chauvin, H. Zarour, 2020, Journal for ImmunoTherapy of Cancer.

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014

Martin F. Mihm, B. Schilling, F. Marincola, 2013, Journal of Translational Medicine.

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

F. Marincola, J. Taube, G. Botti, 2013, Journal of Translational Medicine.

Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses.

H. Zarour, W. Olson, L. Gesualdo, 2000, Blood.

HLA-DP4, the Most Frequent HLA II Molecule, Defines a New Supertype of Peptide-Binding Specificity1

Alain Sanson, H. Zarour, A. Ménez, 2002, The Journal of Immunology.

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)

P. Ascierto, C. Gridelli, H. Zarour, 2018, Journal of Immunotherapy for Cancer.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)

R. Sullivan, P. Ascierto, J. Brugarolas, 2018, Journal of Immunotherapy for Cancer.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

Reversing T-cell Dysfunction and Exhaustion in Cancer

H. Zarour, 2016, Clinical Cancer Research.

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

J. Badger, D. Davar, A. Dzutsev, 2022, Nature Medicine.

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2015, The Journal of clinical investigation.

T lymphocyte responses effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ thaw cell lysates define an - Mature dendritic cells pulsed with freeze

H. Zarour, W. Olson, L. Gesualdo, 2013 .

Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016

J. Taube, P. Ascierto, G. Ciliberto, 2017, Journal of Translational Medicine.

Targeting novel inhibitory receptors in cancer immunotherapy.

Joe-Marc Chauvin, Quanquan Ding, H. Zarour, 2020, Seminars in immunology.

Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors.

D. Davar, H. Zarour, 2019, Methods in molecular biology.

D. Davar, Y. Najjar, J. Kirkwood, 2021, Frontiers in Oncology.

Cross-Reactive CD4+ T Cells against One Immunodominant Tumor-Derived Epitope in Melanoma Patients1

J. Kirkwood, H. Zarour, M. Amicosante, 2007, The Journal of Immunology.

Melanoma Patients inImmunodominant Tumor-Derived Epitope T Cells against One + Cross-Reactive CD 4

J. Kirkwood, H. Zarour, M. Amicosante, 2007 .

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

Ornella Pagliano, J. Kirkwood, H. Zarour, 2012, Cancer research.

NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.

V Brusic, V. Brusic, J. Kirkwood, 2000, Cancer research.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

J. Wolchok, H. Zarour, A. Ribas, 2016, JAMA.

Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)

J. Taube, R. Sullivan, P. Ascierto, 2020, Journal of Translational Medicine.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.

J. Wolchok, H. Zarour, A. Ribas, 2018 .

Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family

Christine Almunia, Dominique Charron, H. Zarour, 2007, Cancer Immunology, Immunotherapy.

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF‐3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma

B. Redman, H. Zarour, S. O’Day, 2009, Cancer.

NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.

V. Brusic, J. Kirkwood, H. Zarour, 2002, Cancer research.

Immunotherapy in lung cancer.

M. Socinski, H. Zarour, A. Kalyan, 2014, Translational lung cancer research.

Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma

J. Kim, D. Davar, Amy Rose, 2021, Clinical Cancer Research.

Microenvironment and Immunology CD 8 þ T Cells Speci fi c for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

Ornella Pagliano, J. Kirkwood, H. Zarour, 2012 .

Melan-A/MART-151–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells

V. Brusic, J. Sidney, A. Sette, 2000 .

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Joe-Marc Chauvin, Ornella Pagliano, J. Kirkwood, 2015, Cancer research.

IL 10 and PD-1 Cooperate to Limit the Activity of Tumor-Speci fi c CD 8 þ T Cells

Joe-Marc Chauvin, Ornella Pagliano, J. Kirkwood, 2015 .

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer.

J. Herman, H. Zarour, E. Chu, 2017 .

Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Jedd D. Wolchok, Antoni Ribas, Richard F. Kefford, 2016 .

The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.

Daniel Gillet, Christine Almunia, Bernard Maillere, 2003, Cancer research.

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.

V. Brusic, J. Sidney, A. Sette, 2000, Proceedings of the National Academy of Sciences of the United States of America.

CD226 opposes TIGIT to disrupt Tregs in melanoma.

D. Davar, Joe-Marc Chauvin, Carmine Menna, 2018, JCI insight.

Absence of γ-Interferon–inducible Lysosomal Thiol Reductase in Melanomas Disrupts T Cell Recognition of Select Immunodominant Epitopes

P. Cresswell, H. Zarour, M. Marić, 2002, The Journal of experimental medicine.

Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis

J. Herman, H. Zarour, R. Pai, 2022, Clinical Epigenetics.

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)

J. Wolchok, H. Zarour, A. Ribas, 2014, Journal of Immunotherapy for Cancer.

303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results

D. Davar, Joe-Marc Chauvin, R. DeBlasio, 2020 .

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma

D. Davar, Joe-Marc Chauvin, R. DeBlasio, 2020, Clinical Cancer Research.

Microbiome-derived metabolites counteract tumor-induced immunosuppression and boost immune checkpoint blockade.

H. Zarour, 2022, Cell metabolism.

The microbiome: a basis for novel immunomodulation in mice and men.

H. Zarour, 2017, Clinical advances in hematology & oncology : H&O.

Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment

Stacy L. Gelhaus, D. Davar, J. McCulloch, 2023, Cell.

In memoriam: Soldano Ferrone, MD, PhD (1940–2023)

H. Zarour, T. Whiteside, 2023, Journal for ImmunoTherapy of Cancer.

Phase IB study of pembrolizumab (Pembro) and pegylated-interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL).

D. Davar, Joe-Marc Chauvin, Ornella Pagliano, 2016 .

The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019

P. Ascierto, H. Zarour, A. Testori, 2020, Journal of Translational Medicine.

Abstract IA38: Manipulating the gut microbiome to improve immunotherapy of melanoma

J. Badger, D. Davar, Carmine Menna, 2019, Microbiome and Metabolism.

Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.

J. Wolchok, H. Zarour, A. Ribas, 2013 .

Targeting PD-1 and Tim-3 pathways to reverse tumor antigen-specific CD4+ T cell dysfunction in patients with advanced melanoma (66.1)

J. Kirkwood, H. Zarour, V. Kuchroo, 2011, Journal of Immunology.

Future perspectives in melanoma research

F. Marincola, J. Taube, G. Botti, 2016, Journal of Translational Medicine.

Categories of Tumor Antigens

H. Zarour, A. Deleo, O. Finn, 2003 .

Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016

J. Taube, P. Ascierto, G. Ciliberto, 2017, Journal of Translational Medicine.

Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma.

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2015 .

A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma

D. Davar, Hong Wang, Y. Najjar, 2022, Journal of the American Academy of Dermatology.

[Basal-cell and linear unilateral adnexal hamartoma (or linear unilateral basal-cell nevus)].

H. Zarour, J. Grob, J. Bonerandi, 1992, Annales de dermatologie et de vénéréologie.

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

J. Lunceford, J. Wolchok, H. Zarour, 2014 .

Future perspectives in melanoma research

F. Marincola, J. Taube, G. Botti, 2016, Journal of Translational Medicine.

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014

Martin F. Mihm, B. Schilling, F. Marincola, 2013, Journal of Translational Medicine.

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

F. Marincola, J. Taube, G. Botti, 2013, Journal of Translational Medicine.

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma

D. Davar, Y. Najjar, J. Kirkwood, 2023, Journal for ImmunoTherapy of Cancer.

CPG 7909, a TLR9 agonist immunomodulator in metastatic melanoma: A randomized phase II trial comparing two doses and in combination with DTIC

B. Redman, H. Zarour, J. Weber, 2005 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma.

L. Xerri, H. Zarour, J. Grob, 1995, Archives of dermatology.

Melanoma and microbiota: Current understanding and future directions.

D. Davar, H. Zarour, G. Hospers, 2023, Cancer cell.

Identifying genes with cell-type-specific alternative polyadenylation in multi-cluster single-cell transcriptomics data

Robert M. Morrison, H. Zarour, Yidi Qin, 2020 .

Epitope Hierarchy of Spontaneous CD4+ T Cell Responses to LAGE-1

J. Kirkwood, H. Zarour, B. Maillère, 2011, The Journal of Immunology.

A Pooled analysis of 655 patients with advanced melanoma enrolled in keynote-001 : long-term efficacy of pembrolizumab (mk-3475)

J. Wolchok, H. Zarour, A. Ribas, 2015 .

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

D. Davar, Joe-Marc Chauvin, Carmine Menna, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy

D. Davar, H. Zarour, A. Karunamurthy, 2024, The oncologist.